BlossomHill (BLSM) 10% Owner Li Yishan Converts Derivatives, Receives Award

What Happened

• Li Yishan, reported as a 10% owner of BlossomHill Therapeutics (BLSM), converted several derivative securities into common stock and was granted 112,701 shares as an award.
• Conversions recorded on 2026-08-10: 1,600,682 shares, 113,435 shares, and 124,779 shares (reported as conversions of derivative securities). A separate grant/award of 112,701 shares (recorded 2026-08-06) was reported at $0.00. Prices for the conversions are listed as N/A; the award shows $0.00 (derivative award). No open-market purchases or sales were reported.

Key Details

• Transaction dates: grant/award reported 2026-08-06; conversions reported 2026-08-10. Filing date: 2026-08-10 (appears timely under Form 4 rules).
• Specific reported amounts: conversions of 1,600,682; 113,435; and 124,779 shares; plus a 112,701-share award. Conversion entries are shown both as acquired (common) and disposed (derivative), reflecting conversion of the underlying instruments.
• Price/Value: conversion prices listed N/A; award price $0.00. No total dollar values reported.
• Shares owned after the transactions are not specified in the provided excerpt.
• Footnotes of note:
  • F1: Series Angel and Series B preferred automatically convert 1:1 into common stock upon IPO closing (no further consideration).
  • F2: Some shares are held in a family trust for which Li and spouse are trustees.
  • F3: Reporting person is manager of RongShan, LLC and disclaims beneficial ownership of securities held by that entity.
  • F4: The 112,701-share award is subject to vesting: 1/4 vests Aug 6, 2027, remainder vests monthly over the next 36 months.

Context

• These actions are internal restructurings/awards, not open-market buys or sells; conversions reflect moving from preferred/derivative instruments into common stock (per F1), and the 112,701-share award is subject to time-based vesting (not immediately sellable if unvested).
• As a 10% owner, Li Yishan’s filings reflect ownership and conversions at an institutional/owner level rather than routine executive market trading.